The following slide presentations have been made available by the presenters. Some files are large and may have long download times. These files are for your review only. They should not be distributed without written consent from the authors. The files are in Adobe7 Acrobat PDF format. Click here for a free copy of the latest Adobe PDF Reader.
Cancer Progress 2012 Slides
March 6-7, 2012
The Westin New York at Times Square
Note: Some slides have not yet been posted and are awaiting approval from the panelist. We will alert you as these become available.
Tuesday, March 6, 2012
Opening Remarks
Click here for the session audio
Jeff Bockman, PhD, Vice President, Defined Health
Future of cancer therapy – Where have we been, where are we going?
Moderator: Neal Rosen, MD, Professor of Medicine, Memorial Sloan-Kettering Cancer Center
Panelists:
- Steven Averbuch, MD, Vice President, Early Global Clinical Research Oncology & Head, Pharmacodiagnostics, Bristol-Myers Squibb Company
- Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs; Medical Director, Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology, Memorial Sloan-Kettering Cancer Center
- Geert Kolvenbag MD, PhD, Global Product Vice President, AstraZeneca
Keynote address: Angiogenesis
George D. Yancopoulos, MD, PhD, Executive Vice President, Chief Scientific Officer, and President, Regeneron Research Laboratories
Novel approaches in cancer drug development and clinical trials – Are we adapting and adopting fast enough?
Click here for the session audio
Moderator: Jamie Freedman, MD, PhD, Vice President, Cancer Research, Oncology, GlaxoSmithKline
Panelists:
- Richard Gaynor, MD, Vice President, Cancer Research & Global Oncology Platform Leader, Eli Lilly and Company
- Eric Rowinsky, MD, Chief Medical Officer, Head of Research and Development, Executive Vice President of Stemline Therapeutics
- Robert Iannone, MD, Section Head, Oncology Clinical Research, Merck Research Laboratories
Immunotherapy for cancer – Are we there yet? The Rights and wrongs of developing next generation immunotherapies
Moderator: Mary L. (Nora) Disis, MD, Associate Dean of Translational Health Sciences, Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology, University of Washington School of Medicine, Member, Fred Hutchinson Cancer Research Center
Panelists:
- Jedd Wolchok, MD, PhD, Associate Attending Physician, Memorial Sloan-Kettering Cancer Center
- H. Kim Lyerly MD, FACS, George Barth Gellar Professor of Cancer Research, Professor of Surgery, Associate Professor of Pathology, Assistant Professor of Immunology, Duke University School of Medicine
- Jon Wigginton, MD, Executive Director, Therapeutic Area Head, Discovery-Medicine Immuno-Oncology, Bristol-Myers Squibb Company
- James Trager, PhD, Sr. Director, Research, Dendreon Corporation
Apoptosis – Why has drug development in apoptosis been stymied?
Moderator: Douglas R. Green, PhD, Chair, Immunology, St. Jude Children’s Research Hospital
Panelists:
- Tak Mak, PhD, Director, The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute; University Professor, University of Toronto
- David Weng, MD, PhD, Chief Medical Officer, TetraLogic Pharmaceuticals
- John C. Reed, MD, PhD, CEO, Professor and Donald Bren Chief Executive Chair, Apoptosis and Cell Death Research, Sanford-Burnham Medical Research Institute
Data, data everywhere – Generating, harvesting, and analyzing the vast fields of cancer information
Moderator: Colin Hill, Chief Executive Officer, President & Chairman, GNS Healthcare
Panelists:
- Eric Schadt, PhD, Chief Scientific Officer, Pacific Biosciences, Jean C. and James W. Crystal Professor of Genomics; Professor and Chairman, Department of Genetics and Genomic Sciences; Director, Institute for Genomics and Multiscale Biology, The Mount Sinai School of Medicine
- Alexis Borisy, Partner, Third Rock Ventures
- Bryan M. Dechairo, PhD, Senior Director, Extramural R&D Head, Medco Health Solutions
Melanoma: Tackling the intractable – But what next?
Moderator: Danny Welch, PhD, Associate Director of Basic Science, KU Cancer Center, Professor & Chair of Cancer Biology, Kansas Bioscience Authority Eminent Scholar, The Kansas University Medical Center
Panelists:
- Jedd Wolchok, MD, PhD, Associate Attending Physician, Memorial Sloan-Kettering Cancer Center
- Paul Chapman, MD, Professor of Medicine, Weill Cornell Medical College, Attending Physician, Memorial Sloan-Kettering Cancer Center
- David E. Fisher, MD, PhD, Chief, Department of Dermatology, Director, Melanoma Program, MGH Cancer Center, Director, Cutaneous Biology Research Center, Massachusetts General Hospital, Edward Wigglesworth Professor of Dermatology – Harvard Medical School
Wednesday, March 7, 2012
Opening Remarks
Click here for the session audio
Mike Rice, Senior Consultant, Defined Health
Keynote: Hematology state of the art
Kenneth C. Anderson, MD, Director, Clinical Research, Kraft Family Professor of Medicine, Harvard Medical School, LeBow Institute for Myeloma Therapeutics & Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
Ovarian Cancer: Response followed by relapse – When will we shift the paradigm?
Moderator: Laura K. Shawver, PhD, Founder, The Clearity Foundation
Panelists:
- Robert C. Bast, Jr., MD, Vice President for Translational Research, The University of Texas MD Anderson Cancer Center
- Douglas A. Levine, MD, Head, Gynecology Research Laboratory, Associate Attending Surgeon, Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center
- Geert Kolvenbag MD PhD, Global Product VP, Olaparib, AstraZeneca
Novel MOAs and targets for cancer drug development – What’s hot off the presses?
Click here for the session audio
Moderator: Jeremy Goldberg, President, JPG Healthcare LLC
Panelists:
- Robert J Schneider, PhD, Associate Director, NYU Cancer Institute Director, Translational Cancer Research Co-director, Breast Cancer Research Program
- Paul B. Fisher, MPh, PhD, Professor and Chairman, Department of Human & Molecular Genetics, Founding Director, VCU Institute of Molecular Medicine, Virginia Commonwealth University (VCU) School of Medicine, Thelma Newmeyer Corman Chair in Cancer Research, VCU Massey Cancer Center
- Carlo M. Croce, MD, The John W. Wolfe Chair in Human Cancer Genetics, The Ohio State University, Chairman, Dept. of Molecular Virology, Immunology and Medical Genetics, Director, Institute of Genetics
- Philip W. Kantoff, MD, Chief Clinical Research Officer, Chief, Division of Solid Tumor Oncology, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
ROI in cancer — How successful has drug discovery and development been in cancer?
Click here for the session audio
Moderator: Mark J. Simon, Advisor, Torreya Partners LLC
Panelists:
- George S. Golumbeski, PhD, Senior Vice President, Business Development, Celgene Corporation
- Julio Gagne, Director Portfolio & Asset Strategy, Oncology & Immunology, Bristol-Myers Squibb Company
- Srinivas Akkaraju, MD, PhD, Managing Director, New Leaf Venture Partners
Comparative effectiveness and reimbursement – Are we setting the bar sufficiently high? From Proof of Concept to Proof of Relevance
Click here for the session audio
Panelists:
- Debra Schrag, MD, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute
- Bryan M. Dechairo, PhD, Senior Director, Extramural R&D Head, Medco Health Solutions
- Usman Iqbal, MD, MPH, MBA, Director, Oncology-Global Evidence & Value Development (EVD), Sanofi
Keynote Speaker:
Click here for the session audio
Mark McClellan, MD, PhD, Director, Engelberg Center for Health Care Reform, Senior Fellow, Economic Studies, Leonard D. Schaeffer Chair in Health Policy Studies, The Brookings Institution
Biomarkers, Companion Diagnostics and Enabling Technologies and Services for Personalized Medicine
Moderator: Brian Leyland-Jones, MD, PhD, Professor of Medicine, Department of Medicine, Emory University
Panelists:
- David Litwack, PhD, Health Scientist & AAAS Science & Technology Policy Fellow Office of Biorepositories and Biospecimen Research National Cancer Institute
- Andrew Allen, MD, PhD, Chief Medical Officer and EVP of Clinical and Pre-Clinical Development, Clovis Oncology
- Scott D. Patterson, PhD, Executive Director, Medical Sciences, Amgen, Inc.
- Doug Ward, Vice President and General Manager, Translational Diagnostics, Ventana Medical Systems
- Gary Kelloff, MD, Special Advisor, Division of Cancer Treatment and Diagnosis, National Cancer Institute
- Steven Averbuch, MD, Vice President, Early Global Clinical Research Oncology & Head, Pharmacodiagnostics, Bristol-Myers Squibb Company
Supporting Organization:
